Search the GHTC website

Global health R&D delivers for North Dakota

US government investment in global health R&D has delivered

$9.2 million
to North Dakota research institutions
North Dakota's top USG-funded global health R&D institutions

North Dakota's top USG-funded global health R&D institutions

University of North Dakota
$8.3 million
North Dakota State University
$901 thousand

North Dakota's top areas of global health R&D by USG funding

Diarrheal diseases
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Multi-disease/health area R&D
Global health R&D at work in North Dakota

Researchers at the University of North Dakota (UND) are studying how, at a cellular level, the respiratory syncytial virus (RSV) causes inflammation of the lungs. While RSV typically causes cold-like symptoms in healthy adults, it can be deadly for infants, particularly those living in low-resource settings worldwide who cannot access hospital care during severe cases. Globally, RSV is the second leading cause of death during the first year of a baby’s life. The research at UND could lead to a better understanding of this disease and thus, improved approaches to treat it. While RSV vaccines were recently approved for adults over 60 years of age, there are no approved vaccines for infants nor specifically approved therapeutics.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: FDA/Michael J. Ermarth